Synaptogenix Inc (SNPX)

Dec 20, 2024, 9:15 AM EST - 4 weeks ago

Synaptogenix Board of Directors Forms Special Committee to Explore Value Creation Opportunities Utilizing Balance Sheet Strength

Sep 11, 2024, 9:00 AM EDT - 4 months ago

Synaptogenix Announces $5.0 Million Financing

Jul 18, 2024, 9:00 AM EDT - 6 months ago

Synaptogenix Announces New Collaboration with LSU Health New Orleans for Study of Proprietary Analogs in Spinal Cord Injury

Jun 26, 2024, 9:00 AM EDT - 7 months ago

Synaptogenix Announces FDA Authorization of IND Application for Clinical Trial for Bryostatin-1 in Multiple Sclerosis

May 7, 2024, 9:00 AM EDT - 9 months ago

Synaptogenix Applauds DEA Proposal to Reclassify Cannabis and Shares Expected Benefits to Cannasoul for Cannabinoid-Based Drug Discovery

Apr 24, 2024, 9:15 AM EDT - 9 months ago

Synaptogenix Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing

Apr 3, 2024, 8:00 AM EDT - 10 months ago

Synaptogenix Announces Reverse Stock Split to Maintain Nasdaq Listing

Dec 19, 2023, 9:00 AM EST - 1 year ago

Synaptogenix President Daniel L. Alkon, M.D.

Dec 6, 2023, 9:00 AM EST - 1 year ago

Synaptogenix Joins Leading Neuroscientists and Academics as Speaker at USC-Sponsored Forum on Age-Related Diseases including Alzheimer's

Nov 2, 2023, 9:00 AM EDT - 1 year ago

Synaptogenix Acquires Significant Stake in Cannasoul Analtyics Ltd. Co-founded by The Technion - Israel Institute of Technology

Sep 26, 2023, 9:00 AM EDT - 1 year ago

Synaptogenix Announces Peer-Reviewed Publication of NIH-Sponsored Phase 2 Clinical Trial Results Demonstrating Safe, Significant, and Persistent Benefits of Bryostatin-1 in Advanced Alzheimer's Disease

Sep 7, 2023, 9:00 AM EDT - 1 year ago

Bryostatin-1 from Synaptogenix Shows Statistically Significant Results as an ALS Treatment in Pre-Clinical Independent Study

Jul 19, 2023, 9:00 AM EDT - 1 year ago

Synaptogenix and Cleveland Clinic to Submit Investigational New Drug (IND) Application to FDA for Clinical Trial of Bryostatin-1 in Multiple Sclerosis

Jul 13, 2023, 9:00 AM EDT - 1 year ago

Synaptogenix Abstract Highlighting Bryostatin-1 Benefits in Severe Alzheimer's Disease Accepted for Presentation at 11th International Brain Research Organization World Congress of Neuroscience

Mar 7, 2023, 9:00 AM EST - 2 years ago

Synaptogenix Provides Corporate Update and Outlines Potential Business Opportunities

Jan 19, 2023, 8:58 AM EST - 2 years ago

5 Health Care Stocks That Are Diving - And May Rally

FATE IPSC TECH

Dec 16, 2022, 9:00 AM EST - 2 years ago

Synaptogenix Announces Topline Results from NIH-Sponsored Phase 2 Clinical Trial of Bryostatin-1 for Advanced Alzheimer's Disease

Dec 9, 2022, 11:50 AM EST - 2 years ago

Synaptogenix: Bryostatin For Alzheimer's, As Binary As Can Be

Nov 18, 2022, 9:00 AM EST - 2 years ago

Synaptogenix Announces $15 Million Private Placement with Existing Investors

Oct 19, 2022, 9:00 AM EDT - 2 years ago

Synaptogenix to Present at ThinkEquity Investor Conference on October 26, 2022

Sep 28, 2022, 11:50 AM EDT - 2 years ago

Synaptogenix Welcomes Lecanemab Phase 3 Trial Results

Aug 12, 2022, 9:00 AM EDT - 2 years ago

Synaptogenix Announces Live Appearance of its President and CSO on Streaming Financial News Network

Jul 26, 2022, 9:15 AM EDT - 2 years ago

Synaptogenix Announces Changes to Scientific Advisory Board in Preparation for Phase 2 Data

Jul 21, 2022, 9:15 AM EDT - 2 years ago

Synaptogenix Announces Corporate Update Conference Call

Jul 20, 2022, 9:15 AM EDT - 2 years ago

Synaptogenix Advances Dosing of First Patient in Dose Optimization Clinical Trial in Preparation for NIH-Sponsored, Phase 2 Alzheimer's Disease Trial Data

May 17, 2022, 9:15 AM EDT - 2 years ago

Synaptogenix to Present at the Cell Symposium

Apr 19, 2022, 9:15 AM EDT - 2 years ago

Synaptogenix Completes Patient Enrollment in NIH Sponsored Phase 2b Alzheimer's Disease Trial

Apr 5, 2022, 9:15 AM EDT - 3 years ago

New Peer Reviewed Article Demonstrates Extended Therapeutic Potential of Synaptogenix's Bryostatin for Alzheimer's Disease

Mar 29, 2022, 9:15 AM EDT - 3 years ago

Synaptogenix to Present at Hanson Wade 10th Annual Neurodegenerative Drug Development Summit

Mar 22, 2022, 9:15 AM EDT - 3 years ago

Synaptogenix to Present at Sachs 5th Annual Neuroscience Innovation Forum

Mar 15, 2022, 9:15 AM EDT - 3 years ago

Synaptogenix to Present Research Highlighting Potential Broad Applicability for Lead Compound Bryostatin at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2022)

Feb 23, 2022, 9:15 AM EST - 3 years ago

Synaptogenix Moves Forward with Clinical Development Plans for Bryostatin-1 as a Treatment for Multiple Sclerosis

Feb 1, 2022, 9:15 AM EST - 3 years ago

Synaptogenix Announces Publication of Peer-Reviewed Scientific Article Evidencing Byrostatin-1's Improved Cognition Over Baseline in Advanced Alzheimer's Disease Patients

Nov 16, 2021, 11:07 PM EST - 3 years ago

Synaptogenix: High-Risk High-Reward For Potential Alzheimer's Disease Treatment

Nov 15, 2021, 9:28 AM EST - 3 years ago

5 Short Squeeze Candidates To Watch: Huadi Tops List, Altimeter Group And Bit Digital Rejoin Leaderboard

BTBT HUDI

Oct 5, 2021, 9:14 AM EDT - 3 years ago

Rebuilding Connections, Fostering Growth: Synaptogenix Could Be A Beacon of Hope for Patients With Neurological Diseases

Sep 10, 2021, 9:00 AM EDT - 3 years ago

Synaptogenix Announces Participation at the H.C. Wainwright 23rd Annual Global Investment Conference

Aug 5, 2021, 10:00 AM EDT - 3 years ago

Synaptogenix Signs Memorandum Of Understanding with Nemours A.I. DuPont Hospital to Initiate Trial Using Bryostatin, Under Orphan Drug Status, to Treat Fragile X Syndrome

Jul 26, 2021, 1:47 PM EDT - 3 years ago

Synaptogenix Stock Drops After Unveiling Analyses Of Alzheimer's Candidate

Jul 26, 2021, 9:15 AM EDT - 3 years ago

Synaptogenix Discloses Positive Results of Further Bryostatin Trial Analyses in Presentation at Alzheimer's Association International Conference 2021

Jul 21, 2021, 9:00 AM EDT - 3 years ago

Synaptogenix Announces Conference Call to Discuss AAIC Abstract Findings

Jul 14, 2021, 9:00 AM EDT - 3 years ago

Synaptogenix to Present Data at Alzheimer's Association International Conference 2021 Highlighting Bryostatin Restores Cognitive Function Above Baseline

Jul 7, 2021, 9:00 AM EDT - 3 years ago

Synaptogenix Announces Regenerative Patent Award to Treat Alzheimer's Disease

Jun 16, 2021, 4:06 PM EDT - 3 years ago

Synaptogenix: The Next Big Thing In Alzheimer's

Jun 14, 2021, 9:00 AM EDT - 3 years ago

Synaptogenix Announces $12.5 Million Private Placement

Jun 9, 2021, 1:25 PM EDT - 3 years ago

Synaptogenix's Alzheimer's Candidate Displays Signs Of Safety In Mid-Stage Study

Jun 9, 2021, 9:00 AM EDT - 3 years ago

Synaptogenix Announces Phase 2b NIH Sponsored Alzheimer's Disease Trial Update

Jun 7, 2021, 11:44 AM EDT - 3 years ago

Synaptogenix Responds to FDA Approval of Aducanumab

Jun 7, 2021, 9:00 AM EDT - 3 years ago

Synaptogenix Announces Approval for Nasdaq Stock Market Listing

May 19, 2021, 9:00 AM EDT - 3 years ago

Synaptogenix Announces Plan to Uplist on the Nasdaq Stock Market